N Freemantle

Summary

Affiliation: University of York
Country: UK

Publications

  1. ncbi Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals?
    N Freemantle
    Medicines Evaluation Group, Centre for Health Economics, University of York, Heslington, UK
    Health Policy 46:255-65. 1999
  2. ncbi A randomized trial of Evidence-based OutReach (EBOR): rationale and design
    N Freemantle
    Centre for Health Economics, University of York, Heslington, United Kingdom
    Control Clin Trials 20:479-92. 1999
  3. ncbi Sleeping with the enemy? A randomized controlled trial of a collaborative health authority/industry intervention to influence prescribing practice
    N Freemantle
    Medicines Evaluation Group, Centre for Health Economics, University of York, UK
    Br J Clin Pharmacol 49:174-9. 2000
  4. ncbi The importance of achieving additional drug benefits at a reasonable cost. A review of the fluoxetine years
    N Freemantle
    Centre for Health Economics, University of York, England
    Pharmacoeconomics 17:319-24. 2000
  5. ncbi Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis
    N Freemantle
    Medicines Evaluation Group, Centre for Health Economics, University of York, Heslington, York YO10 5DD, UK
    Br J Psychiatry 177:292-302. 2000
  6. ncbi A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines
    J Mason
    Medicines Evaluation Group Centre for Health Economics, University of York, Heslington, UK
    Health Policy 47:37-52. 1999
  7. ncbi Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction
    J Mason
    Medicines Evaluation Group, Centre for Health Economics University of York, York YO10 5DD
    BMJ 321:1113-6. 2000
  8. ncbi Publication bias in clinical trials and economic analyses
    N Freemantle
    Centre for Health Economics, University of York, England
    Pharmacoeconomics 12:10-6. 1997
  9. ncbi The dilemma of new drugs. Are costs rising faster than effectiveness?
    J Mason
    Centre for Health Economics, University of York, Heslington, England
    Pharmacoeconomics 13:653-7. 1998

Detail Information

Publications9

  1. ncbi Does the UK National Health Service need a fourth hurdle for pharmaceutical reimbursement to encourage the more efficient prescribing of pharmaceuticals?
    N Freemantle
    Medicines Evaluation Group, Centre for Health Economics, University of York, Heslington, UK
    Health Policy 46:255-65. 1999
    ..It is not clear that the current proposals for reform from the UK Department of Health go far enough to achieve the required changes in drug licensing and regulation...
  2. ncbi A randomized trial of Evidence-based OutReach (EBOR): rationale and design
    N Freemantle
    Centre for Health Economics, University of York, Heslington, United Kingdom
    Control Clin Trials 20:479-92. 1999
    ..The study design addresses important factors that may influence the effectiveness of the intervention, such as the pharmacist who delivers the messages, the health authority in which practices are located, and the size of a practice...
  3. ncbi Sleeping with the enemy? A randomized controlled trial of a collaborative health authority/industry intervention to influence prescribing practice
    N Freemantle
    Medicines Evaluation Group, Centre for Health Economics, University of York, UK
    Br J Clin Pharmacol 49:174-9. 2000
    ..To evaluate the effectiveness of a health authority/pharmaceutical company collaborative intervention to influence the choice of proton pump inhibitors..
  4. ncbi The importance of achieving additional drug benefits at a reasonable cost. A review of the fluoxetine years
    N Freemantle
    Centre for Health Economics, University of York, England
    Pharmacoeconomics 17:319-24. 2000
    ..We note that the road to success was not problem free for fluoxetine, and highlight the response of the sponsor in the development of subsequent drugs for CNS disorders...
  5. ncbi Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis
    N Freemantle
    Medicines Evaluation Group, Centre for Health Economics, University of York, Heslington, York YO10 5DD, UK
    Br J Psychiatry 177:292-302. 2000
    ..There is uncertainty about the contribution of specific pharmacological properties to the efficacy of antidepressants...
  6. ncbi A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines
    J Mason
    Medicines Evaluation Group Centre for Health Economics, University of York, Heslington, UK
    Health Policy 47:37-52. 1999
    ..The implications of this method are discussed, guidance offered for economists new to guideline development and future areas of work identified...
  7. ncbi Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction
    J Mason
    Medicines Evaluation Group, Centre for Health Economics University of York, York YO10 5DD
    BMJ 321:1113-6. 2000
    ..To estimate the costs and consequences of diagnosing symptomatic heart failure with left ventricular systolic dysfunction and initiating angiotensin converting enzyme inhibitors in primary care...
  8. ncbi Publication bias in clinical trials and economic analyses
    N Freemantle
    Centre for Health Economics, University of York, England
    Pharmacoeconomics 12:10-6. 1997
    ....
  9. ncbi The dilemma of new drugs. Are costs rising faster than effectiveness?
    J Mason
    Centre for Health Economics, University of York, Heslington, England
    Pharmacoeconomics 13:653-7. 1998
    ....